523 related articles for article (PubMed ID: 22731961)
1. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
Mathews DC; Henter ID; Zarate CA
Drugs; 2012 Jul; 72(10):1313-33. PubMed ID: 22731961
[TBL] [Abstract][Full Text] [Related]
2. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
Hillhouse TM; Porter JH
Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
4. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
5. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
6. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
[TBL] [Abstract][Full Text] [Related]
7. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
8. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
10. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
11. Ketamine and the next generation of antidepressants with a rapid onset of action.
Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
13. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
[TBL] [Abstract][Full Text] [Related]
14. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
15. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Gerhard DM; Wohleb ES; Duman RS
Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
[TBL] [Abstract][Full Text] [Related]
16. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
17. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
18. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
[TBL] [Abstract][Full Text] [Related]
19. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for major depressive disorder.
Connolly KR; Thase ME
Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
